Category: News

National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries

Editas and AskBio, today announced the companies have entered a strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological diseases.

Expands AAV gene therapy platform from inside the cell for genetic disorders

Certification confirms Viralgen’s commitment to high operational standards with the world’s most flexible and robust AAV manufacturing capability

New $500 million gene therapy manufacturing facility in North Carolina further validates AskBio’s groundbreaking AAV gene therapy accomplishments

Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics

Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orphan genetic diseases.

Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD).

AskBio continues to lead the path for gene therapy development and cost-effective manufacturing methods based on the contributions of its co-founder, Dr. Jude Samulski

Leading gene therapy company announces $235 million investment to accelerate growth